Strategies to control pertussis in infants

Archives of Disease in Childhood

Volumn 98, Issue 7, 2013, Pages 552-555

  Amirthalingam, Gayatri ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

EPIDEMIC; HEALTH PROGRAM; HUMAN; INFANT; INFECTION CONTROL; PERTUSSIS; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM; VACCINATION;

EPIDEMIOLOGY; IMMUNISATION;

ADOLESCENT; COMMUNICABLE DISEASE CONTROL; FEMALE; GREAT BRITAIN; HUMANS; INFANT; INFANT, NEWBORN; PERTUSSIS VACCINE; PREGNANCY; WHOOPING COUGH;

EID: 84879636179     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2012-302968     Document Type: Review

References (51)

1. Joint Committee on Vaccination and Immunisation. JCVI Minutes of the Meeting Held on Monday 9 October 2000. 2000 http://www.dh.gov.uk/prod-consum-dh/ groups/dh-digitalassets/@dh/@ab/documents/digitalasset/dh-117402.pdf
2. Edmunds WJ, Brisson M, Melegaro A, et al. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 2002;20:1316-30. (Pubitemid 34131673)
3. Campbell H, Amirthalingam G, Andrews N, et al. Accelerating the control of pertussis in England and Wales. Emerg Infect Dis 2012;18:38-47.
4. Wendelboe AM, Van Rie A, Salmaso S, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24(Suppl 5):S58-61. (Pubitemid 40676539)
5. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005;115:1422-7. (Pubitemid 43852794)
6. Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Eng J Med 2012;367:1012-19.
7. Laboratory confirmed cases of pertussis reported to the enhanced pertussis surveillance programme (England and Wales): annual report 2011. Health Protection Report 2012;6 http://www.hpa.org.uk/hpr/archives/2012/hpr0812.pdf
8. Confirmed pertussis in England and Wales: data to end December 2012. Health Protection Report 2013;7 http://www.hpa.org.uk/hpr/archives/2013/ news0513.htm#prtsss
9. Rise in whooping cough cases. Northern Ireland: Public Health Agency. http://www.publichealth.hscni.net/news/rise-cases-whooping-cough
10. Increased levels of pertussis circulating in Scotland, 2012 http://www.hps.scot.nhs.uk/ewr/article.aspx
11. Confirmed cases of pertussis in England continues to increase. Health Protection Report 2012;6 http://www.hpa.org.uk/hpr/archives/2012/news1512. htm#prtsss
12. "Pregnant women to be offered whooping cough vaccination ", 28 September 2012. Department of Health website, http://www.dh.gov.uk/health/2012/ 09/whooping-cough/
13. World Health Organization. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010;85:385-400.
14. National and state vaccine coverage amongst adolescents aged 13-17 years - United States, 2011. MMWR 2012;61:671-7.
15. Skoff TH, Cohn AC, Clark TA, et al. Early impact of the US Tdap vaccination program on pertussis trends. Arch Pediatri Adolesc Med 2012;166:344-9.
16. Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008;5:e74.
17. Rohani P, Zhong X, King AA. Contact network structure explains the changing epidemiology of pertussis. Science 2010;330:982-5.
18. Quinn HE, McIntyre PB. The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia. Bull World Health Organ 2011;89:666-74.
19. Lavine JS, Bjørnstad ON, de Blasio BF, et al. Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine. Vaccine 2012;30:544-51.
20. Barreto L, Guasparini R, Meekison W, et al. Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria and 5-component acellular pertussis vaccine. Vaccine 2007;25:8172-79. (Pubitemid 350046319)
21. Kowalzik F, Barbosa AP, Fernandez VR, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis 2007;26:238-42. (Pubitemid 46340771)
22. Wendelboe AM, Hudgens MG, Poole C, et al. Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants. Emerg Themes Epidemiol 2007;4:15.
23. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J 2004;23:985-9. (Pubitemid 40824285)
24. Zepp F, Heininger U, Mertsola J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011;11:557-70.
25. Crowcroft NS, Booy R, Harrison T, et al. Severe and unrecognised: pertussis in UK infants. Arch Dis Child. 2003;88:802-6. (Pubitemid 37094238)
26. Munoz F, Englund J. Infant pertussis: is cocooning the answer? CID 2011;53:893-6.
27. de Greeff SC, Mooi FR, Westerhof A, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 2010;50:1339-45.
28. Halperin BA, Morris A, MacKinnon-Cameron D, et al. Kineticsa of the antibody response to tetanus-diphtherias-acellular pertussis vaccine (Tdap) in women of child bearing age and post partum women. Clin Infect Dis 2011;53:885-92.
29. Healy CM, Rench MA, Baker CJ. Implementation of cocooning against pertussis in a high-risk population. Clin Infect Dis 2011;52:157-62.
30. Belloni C, De Silvestri A, Tinelli C, et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 2003;111:1042-5. (Pubitemid 36542619)
31. Wood N, McIntyre P, Marshall H, et al. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J 2010;29:209-15.
32. Halasa NB, O'Shea A, Shi JR, et al. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr 2008;153: 327-32.
33. Knuf M, Schmitt HJ, Jacquet JM, et al. Booster vaccination after neonatal priming with acellular pertussis vaccine. J Pediatr 2010;156:675-8.
34. Wood N, Siegrist CA. Neonatal immunization: where do we stand? Curr Opin Infect Dis 2011;24:190-5.
35. Shinall MC, Peters TR, Zhu Y, et al. Potential impact of acceleration of the pertussis vaccine primary series for infants. Pediatrics 2008;122:1021-6.
36. Foxwell AR, McIntyre P, Quinn H, et al. Severe pertussis in infants: estimated impact of first vaccine dose at 6 versus 8 weeks in Australia. Pediatr Infect Dis J 2011;30:161-3.
37. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol 2011;204:334, e1-5.
38. Leuridan E, Hens N, Peeters N, et al. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J 2011;30:608-10.
39. Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J 2005;24(5 Suppl):S62-5. (Pubitemid 40676540)
40. Halperin BA, Morris A, Mackinnon-Cameron D, et al. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis 2011;53:885-92.
41. Beytout J, Launay O, Guiso N, et al. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Hum Vaccin 2009;5:315-21.
42. Newell KW, Lehmann D, Leblanc DR, et al. The use of toxoid for the prevention of tetanus neonatorum. Final report of a double-blind controlled field trial. Bull World Health Organ 1966;35:863-71.
43. Schofield FD, Tucker VM, Westbrook GR. Neonatal tetanus in New Guinea. Effect of active immunization in pregnancy. Br Med J 1961;2:785-9.
44. Zheteyeva YA, Moro PL, Tepper NK, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol 2012;207:59, e1-7.
45. Updated Recommendations for Use of Tetanus Toxiod, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) in Pregnant Women and Persons Who Have or Anticipate Having Close Contact with an infant Aged <12 months - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR 2011;60(41):1424-6.
46. Healy CM, Rench MA, Baker CJ. Importance of timing of maternal Tdap immunization and protection of young infants. Clin Infect Dis 2012. Advanced Access.
47. ACIP provisional updated recommendations on use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) for pregnant women, 2012. http://www.cdc.gov/vaccines/recs/provisional/downloads/Tdap- pregnant-Oct-2012.pdf
48. Van Savage J, Decker MD, Edwards KM, et al. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 1990;161:487-92. (Pubitemid 20107950)
49. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 1995;96(3 Pt 2):580-4.
50. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR 2011;60:1424-6.
51. Dalhousie University. Pertussis maternal immunization study. Identifier: NCT00553228. http://clinicaltrials.gov/show/nct00553228 (accessed 27 Mar 13).